Hep G2 Hepatocarcinoma Homogeneous Apoptosis Assay

This protocol describes the monitoring of nanoparticle treated human hepatocarcinoma cells (HepG2) for apoptosis, as part of the in vitro NCL preclinical characterization cascade (1, 2). The protocol utilizes a fluorescent method to measure Caspase-3/7 activation. This is a homogeneous assay that does not require cell isolation, as required for HepG2 Hepatocarcinoma Apoptosis Assay (NCL Method GTA-6).